Clinical trialObservationalRecruiting
FAPI-PET for Tumor Detection
68-Ga-FAPI-PET for Tumor Detection: A Prospective Observational Trial
- Outcome
- Ongoing
- Phase
- Observational
- Status
- Recruiting
- Study type
- Observational
- Start
- 30 April 2020
- Expected end
- 30 April 2027
- Enrollment
- 500 participants
- Sites
- 1
- Primary outcomes
- Correlation between 68Ga-FAPI PET uptake intensity and histopathologic FAP expression. Validation via immunohistochemical FAP staining/molecular analyses of pathological specimen.
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 29 November 2023
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a prospective observational trial investigating correlation with histopathology, positive predictive value, detection rate, reproducibility and impact on clinical management of 68-Ga-FAPI PET/CT or PET/MRI in patients receiving this imaging modality for tumor staging or restaging as part of clinical care.
Detailed description public domain (ClinicalTrials.gov)
68-Ga-fibroblast-activation-protein-inhibitors (68-Ga-FAPI) are novel Positron emission tomography (PET) tracers that were recently introduced for the imaging of patients with various cancer diseases. The fibroblast-activation-protein (FAP) is highly expressed in carcinoma-associated fibroblasts (CAFs) in the stroma of various tumor entities. The aim of this registry study is to collect data on FAPI expression, positive predictive value, detection rate, reproducibility and impact on clinical management of 68-Ga-FAPI PET/CT or PET/MRI on patients receiving this imaging modality at initial diagnosis or restaging as part of clinical care.
Papers 6
- Builds on itComparison between [68Ga]Ga-FAPI-46 and [18F]FDG PET/CT uptake in luminal-like vs. HER2-positive breast cancer. DOI 10.1186/s13550-026-01390-3↗
- Builds on itPrognostic Value of Fibroblast Activation Protein-Directed PET Imaging in Pleural Mesothelioma. DOI 10.2967/jnumed.125.270906↗
- Builds on itHead-to-head comparison of 68 Ga-FAPI-46 PET/CT, 18F-FDG PET/CT, and contrast-enhanced CT for the detection of various … DOI 10.1007/s12149-024-01993-7↗
- Builds on itThe Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue, 68Ga-FAPI-46 PET Dat… DOI 10.2967/jnumed.123.267151↗
- Builds on itFibroblast Activation Protein-Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Sin… DOI 10.2967/jnumed.124.267473↗
- Builds on itPrognostic Implications of 68Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors. DOI 10.2967/jnumed.123.266981↗